>>>>>>(b) and (e). Integer Holdings Corporation (the “Company”) today announced that Antonio Gonzalez has stepped down as the President of the Company’s Cardiac Rhythm Management & Neuromodulation (“CRM&N”) product line effective immediately. Mr. Gonzalez is expected to continue to be employed by the Company until January 3, 2020, at which date he will separate from service with the Company. In connection with Mr. Gonzalez’s separation, (i) he will receive cash severance payments in the aggregate amount of $320,000, (ii) he will remain eligible to receive a pro-rated bonus under the Company’s short-term incentive compensation plan for the Company’s 2019 fiscal year, and (iii) all of the outstanding unvested performance-based equity awards held by Mr. Gonzalez will remain eligible for vesting on a pro-rated basis based upon achievement of the performance goals, in accordance with the terms of the Company’s stock incentive plans. These severance benefits are subject to Mr. Gonzalez signing a separation agreement with the Company containing customary release provisions.

The Company also announced that Joel Becker has been hired to serve as the President of the Company’s CRM&N product line. Mr. Becker, age 51, had a nearly 20-year career with St. Jude Medical, including serving as President of St. Jude Medical’s Americas Division, responsible for Cardiac Rhythm Management, Electrophysiology, Vascular, Structural Heart and Neuromodulation. Mr. Becker will apply his extensive healthcare experience, product knowledge, customer and competitor insights and industry relationships to build on CRM&N’s strong performance as the company executes its strategy to achieve above market growth.